RO 5545965

Drug Profile

RO 5545965

Alternative Names: RO-554965; RO5545965

Latest Information Update: 14 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Schizophrenia

Most Recent Events

  • 24 Apr 2017 Roche completes a phase I trial for Schizophrenia in USA (PO, Capsule) (NCT02824055)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Schizophrenia(In volunteers) in Netherlands (PO, Capsule)
  • 27 Jun 2016 Roche initiates a phase I trial for Schizophrenia in USA (PO, Capsule) (NCT02824055)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top